INFORMATION: The product (substance) is neither a food product nor a dietary supplement and is not suitable for human consumption
This framework is intended to help you structure a productive conversation with your functional medicine provider
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
The initial commercial release of the BPC-157 transdermal patch is described as being planned through The Precision Peptide Company website, located at www.precisionpeptidecompany.com, which suggests an initial direct-to-consumer e-commerce approach
The trial also showed that the combination produced dose-dependent, sustained weight loss without concerning additional adverse effects the side effect profile was broadly consistent with what would be expected from each individual agent
